BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grigg SE, Sarri GL, Gow PJ, Yeomans ND. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2019;49:1260-1273. [PMID: 30989721 DOI: 10.1111/apt.15253] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Grigg SE, Sarri GL, Gow PJ, Yeomans ND. Letter: mechanistic target of rapamycin inhibitors-do they impact on recurrence of hepatocellular carcinoma after liver transplantation? Authors' reply. Aliment Pharmacol Ther 2019;50:117-20. [PMID: 31184392 DOI: 10.1111/apt.15324] [Reference Citation Analysis]
2 Ling S, Feng T, Zhan Q, Duan X, Jiang G, Shen T, Shan Q, Xu S, Ye Q, Liu P, Cen B, Zheng S, Xu X. Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria. Ann Transl Med 2020;8:80. [PMID: 32175373 DOI: 10.21037/atm.2020.01.10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Zhao Y, Liu Y, Zhou L, Du GS, He Q. Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(9): 953-966 [PMID: 34621472 DOI: 10.4240/wjgs.v13.i9.953] [Reference Citation Analysis]
4 Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. World J Clin Oncol 2021; 12(8): 623-645 [PMID: 34513597 DOI: 10.5306/wjco.v12.i8.623] [Reference Citation Analysis]
5 Rodríguez-Perálvarez M, Amado V, de la Mata M. Letter: mechanistic target of rapamycin inhibitors as adjuvant therapy for patients with hepatocellular carcinoma undergoing liver transplantation. Aliment Pharmacol Ther 2019;50:478-9. [PMID: 31359472 DOI: 10.1111/apt.15300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Ohira M, Tanimine N, Kobayashi T, Ohdan H. Essential updates 2018/2019: Liver transplantation. Ann Gastroenterol Surg 2020;4:195-207. [PMID: 32490333 DOI: 10.1002/ags3.12321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jeong YH, Hwang S, Lee GD, Choi SH, Kim HR, Kim YH, Park SI, Kim DK. Surgical Outcome of Pulmonary Metastasectomy for Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Ann Transplant 2021;26:e930383. [PMID: 33972494 DOI: 10.12659/AOT.930383] [Reference Citation Analysis]
8 Cillo U, De Carlis L, Del Gaudio M, De Simone P, Fagiuoli S, Lupo F, Tisone G, Volpes R. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatol Int 2020;14:930-43. [PMID: 33099753 DOI: 10.1007/s12072-020-10091-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 Amer A, Wilson CH, Manas DM. Liver transplantation for unresectable malignancies: Beyond hepatocellular carcinoma. Eur J Surg Oncol 2019;45:2268-78. [PMID: 31387755 DOI: 10.1016/j.ejso.2019.07.024] [Reference Citation Analysis]
10 Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Reference Citation Analysis]
11 Li H, Yang Z, Li R, Lu S, Lu W. Regorafenib Combined With Sirolimus Achieves Successful Treatment of Diffuse Double Lung Metastasis After Liver Transplantation in Giant Liver Cancer Beyond Transplantation Criteria: A Case Report. Transplant Proc 2020;52:634-7. [PMID: 32035675 DOI: 10.1016/j.transproceed.2019.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Bonney GK, Chew CA, Lodge P, Hubbard J, Halazun KJ, Trunecka P, Muiesan P, Mirza DF, Isaac J, Laing RW, Iyer SG, Chee CE, Yong WP, Muthiah MD, Panaro F, Sanabria J, Grothey A, Moodley K, Chau I, Chan ACY, Wang CC, Menon K, Sapisochin G, Hagness M, Dueland S, Line PD, Adam R. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol 2021;6:933-46. [PMID: 34506756 DOI: 10.1016/S2468-1253(21)00219-3] [Reference Citation Analysis]
13 Lee KW, Kim SH, Yoon KC, Lee JM, Cho JH, Hong SK, Yi NJ, Han SS, Park SJ, Suh KS. Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial. J Clin Med 2020;9:E3264. [PMID: 33053849 DOI: 10.3390/jcm9103264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Berenguer M, Burra P, Ghobrial M, Hibi T, Metselaar H, Sapisochin G, Bhoori S, Kwan Man N, Mas V, Ohira M, Sangro B, van der Laan LJW. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1143-9. [PMID: 32217940 DOI: 10.1097/TP.0000000000003196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
15 Tanimine N, Ohira M, Tahara H, Ide K, Tanaka Y, Onoe T, Ohdan H. Strategies for Deliberate Induction of Immune Tolerance in Liver Transplantation: From Preclinical Models to Clinical Application. Front Immunol 2020;11:1615. [PMID: 32849546 DOI: 10.3389/fimmu.2020.01615] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Castellote J, Mora Luján JM, Riera-Mestre A. Letter to the Editor: mTOR-Inhibitor-Based Immunosuppression Following Liver Transplantation for Hereditary Hemorrhagic Telangiectasia. Hepatology 2020;71:762-3. [PMID: 31330053 DOI: 10.1002/hep.30870] [Reference Citation Analysis]
17 Iriarte A, Figueras A, Cerdà P, Mora JM, Jucglà A, Penín R, Viñals F, Riera-Mestre A. PI3K (Phosphatidylinositol 3-Kinase) Activation and Endothelial Cell Proliferation in Patients with Hemorrhagic Hereditary Telangiectasia Type 1. Cells 2019;8:E971. [PMID: 31450639 DOI: 10.3390/cells8090971] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
18 Lu X, Paliogiannis P, Calvisi DF, Chen X. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies. Hepatology 2021;73 Suppl 1:49-61. [PMID: 32394479 DOI: 10.1002/hep.31310] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
19 Cholongitas E. Letter: mechanistic target of rapamycin inhibitors-do they impact on recurrence of hepatocellular carcinoma after liver transplantation? Aliment Pharmacol Ther 2019;50:116-7. [PMID: 31184384 DOI: 10.1111/apt.15310] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Saunders EA, Engel B, Höfer A, Hartleben B, Vondran FWR, Richter N, Potthoff A, Zender S, Wedemeyer H, Jaeckel E, Taubert R. Outcome and safety of a surveillance biopsy guided personalized immunosuppression program after liver transplantation. Am J Transplant 2021. [PMID: 34455702 DOI: 10.1111/ajt.16817] [Reference Citation Analysis]
21 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Houben P, Schimmack S, Unterrainer C, Döhler B, Mehrabi A, Süsal C. Rare Malignant Indications for Liver Transplantation: A Collaborative Transplant Study Report. Front Surg 2021;8:678392. [PMID: 34926560 DOI: 10.3389/fsurg.2021.678392] [Reference Citation Analysis]
23 Tejedor-Tejada J, Alonso-Martín C, Almohalla-Álvarez C, Valenzuela EF, Muñoz RN, Delgado LS, Martín CM, Sánchez-Martín F, García-Pajares F, Sánchez-Antolín G. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis. Transplant Proc 2020;52:1507-10. [PMID: 32213292 DOI: 10.1016/j.transproceed.2020.02.058] [Reference Citation Analysis]
24 Chayanupatkul M, Gambarin-Gelwan M, Schiano TD. The presence of non-hepatic malignancy and its implication in pursuing liver transplantation. Clin Transplant 2021. [PMID: 34189778 DOI: 10.1111/ctr.14410] [Reference Citation Analysis]
25 Yang Z, Wang S, Tian XY, Xie QF, Zhuang L, Li QY, Chen CZ, Zheng SS. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience. Hepatobiliary Pancreat Dis Int 2020;19:365-70. [PMID: 32553774 DOI: 10.1016/j.hbpd.2020.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Jia J, Che L, Cigliano A, Wang X, Peitta G, Tao J, Zhong S, Ribback S, Evert M, Chen X, Calvisi DF. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis. Int J Mol Sci 2020;21:E8467. [PMID: 33187130 DOI: 10.3390/ijms21228467] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
27 Sung PS, Han JW, Seo C, Ahn J, Lee SK, Nam HC, Choi HJ, You YK, Jang JW, Choi JY, Yoon SK. Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant. Front Pharmacol 2021;12:685176. [PMID: 34326770 DOI: 10.3389/fphar.2021.685176] [Reference Citation Analysis]
28 Manzia T, Parente A, Angelico R, Gazia C, Tisone G. The Revolution in Indication for Liver Transplantation: Will Liver Metastatic Disease Overcome the End-Stage Liver Disease in the Next Future? Transplantology 2020;1:111-22. [DOI: 10.3390/transplantology1020011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]